Loading…
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
This bill requires the Centers for Medicare & Medicaid Services to issue guidance for state Medicaid programs on best practices to support individuals with major depressive disorder or other mental health conditions, including options that include pharmacogenetic testing.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2022 · fourth_quarter · Health Issues
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests Legislation on best practices for pharmacogenomic testing; S4633
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov